Diabetic retinopathy is the leading cause of blindness which is associated with excessive angiogenesis. Using the structure of wondonin marine natural products, we previously created a scaffold to develop a novel type of antiangiogenesis agent that possesses minimized cytotoxicity. To overcome its poor pharmaceutical properties, we further modified the structure. A new scaffold was derived in which the stereogenic carbon was changed to nitrogen and the 1,2,3-triazole ring was replaced by an alkyl chain. By comparing the bioactivity versus cytotoxicity, compound was selected, which has improved aqueous solubility and an enhanced selectivity index. Mechanistically, suppressed angiopoietin-2 (ANGPT2) expression induced by high glucose in retinal cells and exhibited antiangiogenic activity in choroidal neovascularization and oxygen-induced retinopathy mouse models. These results suggest the potential of as a lead to develop antiangiogenic small-molecule drugs to treat diabetic retinopathy and as a chemical tool to elucidate new mechanisms of angiogenesis.
Discovery of Novel Small-Molecule Antiangiogenesis Agents to Treat Diabetic Retinopathy.
![Discovery of Novel Small-Molecule Antiangiogenesis Agents to Treat Diabetic Retinopathy.](https://cdn.physiciansweekly.com/wp-content/uploads/2023/08/eye-vision-test-ophthalmology-ophthalmologist-2-1280x640.jpg)